If only Bayer, the German pharmaceutical and agricultural seed and chemical giant, had bothered to ask around before acquiring the American-based Monsanto Company for $63 billion in cash last June.
Two months later a jury delivered a $289 million award (later reduced to $78 million) to a groundskeeper who claimed his frequent exposure to Monsanto’s Roundup weedkiller had given him cancer and that the company covered up the danger. (In 2015 the World Health Organization classified glyphosate, the name of the active ingredient in Roundup, as a probable carcinogen. Glyphosate is one of the most broadly used herbicides in the world.)
There are over 8,000 cases pending against Monsanto in the United States and many more will surely be filed. Bayer’s stock has lost $38 billion in value since Bayer acquired Monsanto. The company would have done better putting its $63 billion in cash into a hole in the ground.